The FDA drugs database lists a supplement dated 19 October 2026 to an approved epinephrine application marketed as Adrenalin. The record gives the applicant and product but not the content of the change.
Nothing in the record suggests a safety finding. The product is a US listing, and nothing in the record bears on adrenaline preparations used in India.
- The supplement relates to NDA 204200 for epinephrine, held by PH Health.
- It was recorded on 19 October 2026.
- Supplements often cover labelling, packaging or manufacturing.
- Label adrenaline by mg/mL rather than ratio to reduce dosing errors.
Why it matters
Adrenaline formulations and labels change often, and confusion between concentrations is a known source of error.
Don't overread it
A licence supplement is not a new indication, and the record does not say what changed.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for emergency & critical care, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free